Kamada Ltd. (NASDAQ:KMDA) Stock to Pay Special Dividend of $0.14

Kamada Ltd. (NASDAQ:KMDA) announced a special dividend on Saturday, November 7th. Shareholders of record on Thursday, November 19th will be given a dividend of $0.14 per share by the biotechnology company on Wednesday, December 9th. The ex-dividend date is Thursday, November 19th.

Kamada has a dividend payout ratio of 30.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Kamada to earn $0.58 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 20.7%.

Kamada Price Performance

Shares of NASDAQ:KMDA traded up $0.48 during trading on Monday, hitting $7.71. 171,844 shares of the company were exchanged, compared to its average volume of 82,330. The firm’s 50 day moving average price is $8.08 and its 200-day moving average price is $8.00. Kamada has a 12-month low of $6.59 and a 12-month high of $9.35. The stock has a market capitalization of $443.36 million, a P/E ratio of 20.29, a PEG ratio of 0.61 and a beta of 0.90.

Kamada (NASDAQ:KMDA) last announced its earnings results on Monday, November 9th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. The firm had revenue of $52.03 million during the quarter, compared to analysts’ expectations of $52.51 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. As a group, equities research analysts anticipate that Kamada will post 0.48 EPS for the current year.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.